| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Reproductive Endocrine Unit of the Department of Medicine (L.W.C., Y.S., L.P., V.A.H., A.A.D., T.R., F.J.H., S.B.S., W.F.C., N.P.), Harvard Reproductive Endocrine Science Center, Massachusetts General Hospital, and Harvard Medical School, Boston, Massachusetts 02114; Department of Pharmacology (C.Z., Q.-Y.Z.), University of California, Irvine, Irvine, California 92697; The Institute for Human Genetics & the School of Clinical Medical Sciences (R.Q.), University of Newcastle-on-Tyne, Newcastle on Tyne NE1 4LP, United Kingdom; Endocrinology Department (D.P., S.P.), San João Hospital, Laboratory of Cell and Molecular Biology, Faculty of Medicine of Porto, and The Institute of Molecular Pathology and Immunology of the University of Porto, 4200–319 Porto, Portugal; Centre de Recherche du Centre Hospitalier Universitaire Sainte-Justine (C.H., N.A.), Montreal, Quebec, H3T 1C5, Canada; Division of Pediatric Endocrinology (P.S.), Schneider Children’s Hospital, New Hyde Park, New York 11040; Endocrine Center (A.T.), Toranomon Hospital and Okinaka Memorial Institute for Medical Research, Tokyo 105-8470, Japan; and Endocrinology Service (G.V.V.), Sainte Justine Hospital, Montréal, Québec, Canada H3T 1C5
Address all correspondence and requests for reprints to: Nelly Pitteloud, M.D., The Harvard Center for Reproductive Endocrine Sciences and the Reproductive Endocrine Unit of the Department of Medicine, Bartlett Hall Extension 5, Massachusetts General Hospital, Boston, Massachusetts 02114. E-mail: npitteloud{at}partners.org.
 |
Abstract |
|---|
 Top Abstract IntroductionSubjects and MethodsResultsDiscussionReferences |
|---|
Objectives: We aimed to screen a large cohort of patients with Kallmann syndrome (KS) and normosmic idiopathic hypogonadotropic hypogonadism (IHH) for mutations in PROK2/PROKR2, evaluate their prevalence, define the genotype/phenotype relationship, and assess the functionality of these mutant alleles in vitro.
Design: Sequencing of the PROK2 and PROKR2 genes was performed in 170 KS patients and 154 nIHH. Mutations were examined using early growth response 1-luciferase assays in HEK 293 cells and aequorin assays in Chinese hamster ovary cells.
Results: Four heterozygous and one homozygous PROK2 mutation (p.A24P, p.C34Y, p.I50M, p.R73C, and p.I55fsX1) were identified in five probands. Four probands had KS and one nIHH, and all had absent puberty. Each mutant peptide impaired receptor signaling in vitro except the I50M. There were 11 patients who carried a heterozygous PROKR2 mutation (p.R85C, p.Y113H, p.V115M, p.R164Q, p.L173R, p.W178S, p.S188L, p.R248Q, p.V331M, and p.R357W). Among them, six had KS, four nIHH, and one KS proband carried both a PROKR2 (p.V115M) and PROK2 (p.A24P) mutation. Reproductive phenotypes ranged from absent to partial puberty to complete reversal of GnRH deficiency after discontinuation of therapy. All mutant alleles appear to decrease intracellular calcium mobilization; seven exhibited decreased MAPK signaling, and six displayed decreased receptor expression. Nonreproductive phenotypes included fibrous dysplasia, sleep disorder, synkinesia, and epilepsy. Finally, considerable variability was evident in family members with the same mutation, including asymptomatic carriers.
Conclusion: Loss-of-function mutations in PROK2 and PROKR2 underlie both KS and nIHH.
|
Introduction |
|---|
|
TopAbstractIntroductionSubjects and MethodsResultsDiscussionReferences |
|---|
Prokineticin 2 (PROK2) and its receptor [prokineticin receptor 2 (PROKR2)] regulate diverse biological processes by the activation of downstream signaling pathways (15, 16). PROK2 is a secreted protein of 81 amino acids, and PROKR2 is a 384 amino acid G protein-coupled receptor. The PROK2 system was initially studied for its involvement in gastrointestinal smooth muscle contraction, angiogenesis, hematopoiesis, and circadian rhythms (17, 18, 19, 20). The knockout models for both ligand and receptor revealed a previously unappreciated role of PROK2 signaling in olfactory bulb (OB) morphogenesis and sexual maturation, suggesting PROK2 and PROKR2 as strong candidate genes for human GnRH deficiency (21, 22, 23). Furthermore, we have recently reported loss-of-function PROK2 mutation in an IHH pedigree with variable olfactory phenotypes (23). In addition, frame shifting and missense mutations in PROK2 and PROKR2 have been identified in a large cohort of probands with KS and variable expressivity of both olfactory and reproductive phenotypes within family members carrying the same gene defect were reported, however, no functional studies were performed on these mutations (9, 14).
Therefore, we aimed to investigate further the role of PROK2/PROKR2 in the pathogenesis of KS and normosmic IHH (nIHH), study the prevalence of mutations, define the bioactivity of the mutant proteins in vitro, and characterize the genotype-phenotype relationship.
|
Subjects and Methods |
|---|
|
TopAbstractIntroductionSubjects and MethodsResultsDiscussionReferences |
|---|
A total of 324 IHH (170 KS, 154 nIHH), including 257 males and 67 females, was studied. GnRH deficiency was characterized by: 1) absent/incomplete puberty by age 18 yr; 2) serum testosterone (T) less than or equal to 100 ng/dl in men, or estradiol (E2) less than or equal to 20 pg/ml in women in association with low or normal levels of serum gonadotropins; 3) otherwise normal pituitary function; 4) normal serum ferritin concentrations; and 5) normal magnetic resonance imaging (MRI) of the hypothalamic-pituitary region.
The control population consisted of 173 healthy Caucasian subjects from Massachusetts General Hospital (MGH) and 34 Asian controls. The study was approved by the Human Research Committee of MGH, and all subjects provided written informed consent before participation.
Phenotyping
A detailed personal and family history of pubertal development and associated nonreproductive phenotypes was obtained. A detailed physical examination was performed. Olfactory acuity was assessed by history and when possible confirmed with quantitative smell testing. A score of less than the fifth percentile based on sex and age was deemed abnormal (24). When possible, a renal ultrasound and a cranial three-dimensional MRI to assess the olfactory system were performed as previously described (25). Patients with mutations in PROK2 or PROKR2 were invited to perform an overnight 12-h frequent blood-sampling study for LH (q10' x 12 h) after withdrawal of hormonal therapy for a suitable washout period (typically 8 wk) at the General Clinical Research Center of MGH. The pool serum was also assayed for FSH, T, E2, and inhibin B (2).
Mutational analysis
Genomic DNA was obtained from leukocytes using a standard extraction procedure. The coding region and intron-exon boundaries of the PROK2 and PROKR2 genes were amplified using the PCR. The PROK2 gene is located on 3p13 (GenBank accession no. NM 021935) and consists of four exons. Screening was performed as previously described (21). The PROKR2 gene is located on 20p12.3 (GenBank accession no. NM 144772) and consists of two exons. The following primers were used: 5'-ACT GAC CCT GAA AGA GCA GAA GGT-3'; 5'-AGC CTG TCA GAG CCT TAA ATG AGG A-3'; 5'-TGA GGA TTC ACT GTG CCA CT-3'; 5'-TTG CGA ATC TGC TCC GTC TG-3'; 5'-TCT TTG GTG TCG AGT TCG TG-3'; and 5'-ACA CAG ATG TCA TTT CCC ATG C-3'. All amplified products were sequenced using the AmpliTaq Dye Terminator Cycle Sequencing kit and an ABI PRISM 377 DNA sequencer (Perkin-Elmer Corp., Foster City, CA). All sequence variations were found on both strands and confirmed in a separate PCR reaction. All nucleotide changes were assessed for their presence in the National Center for Biotechnology Information database of single-nucleotide polymorphisms and the expressed sequence tags database, and among control alleles. In addition, conserved across species of the mutated residue was also assessed. All genes and proteins are described using standard nomenclature (26).
Each proband carrying a mutation in PROK2/PROKR2 was also screened for other known loci involved in IHH [KAL1 (27), FGFR1 (28), GPR54 (13), NELF (10), and GnRHR (29).
In vitro studies
Generation of mutant PROK2 proteins and PROKR2 expression plasmids Mutations in the mature form of PROK2 were introduced into the wild-type (WT) 6xHis-tagged cDNAs in a modified pGEX-3X vector (Amersham Pharmacia Biotech, Piscataway, NJ) using the Quick Change XLII Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA) (15). PROK2 constructs were expressed in BL21 Escherichia coli cells, and tagged proteins were purified from cell lysates by affinity chromatography on Ni-NTA beads (QIAGEN, Inc., Valencia, CA). After digest with factor Xa to remove the tag, the proteins were renatured as previously described. Final purification was performed on reverse phase-HPLC, and the purified product was analyzed by electrospray ionization mass spectrometry using a 6.5-T HiResESI Fourier Transform mass spectrometer (IonSpec, Irvine, CA). The 27 amino acid truncated mutant (I55fsX1) was chemically synthesized as previously reported (21).
Mutations in the coding sequence of PROKR2 were introduced to a V5 C-terminal tagged WT PROKR2 cDNA (16) cloned in pCDNA3.1/V5HisD TOPO expression vector (Invitrogen Corp., Carlsbad, CA) using site-directed mutagenesis as described previously. All constructs were verified by direct nucleotide sequencing.
Ca2+ mobilization assay The ability of PROK2 mutants to activate intracellular Ca2+ mobilization was assessed using an aequorin-based luminescent assay as previously described (16). The same protocol was used to study the PROKR2 mutants except that Chinese hamster ovary (CHO) cells were transiently transfected with WT or mutant PROKR2 plasmids using Lipofectamine (Invitrogen).
Gene transcription reporter assay To evaluate the ability of PROKR2 mutants to activate downstream gene transcription, we developed a luciferase reporter assay using the murine early growth response (Egr)-1 gene promoter, a target of the MAPK signaling cascade (30). The Egr-1 promoter region (–1023 to +1) was amplified by PCR from mouse genomic DNA and inserted into the pGL3-basic vector (31). Using Effectene reagent (QIAGEN), subconfluent HEK293 cells in 48-well plates were transiently transfected with 5 ng WT or mutant PROKR2 plasmid, together with 5 ng Egr-1-luciferase reporter and 140 ng empty vector). Twenty-four hours after transfection, cells were stimulated with increasing doses of WT PROK2 (10–6-10–12 M range) in serum free medium containing 0.1% BSA. After 16-h incubation, the cells were lysed in Passive Lysis Buffer (Promega Corp., Madison, WI), and luciferase induction was analyzed using a Luciferase Assay System (Promega).
Data analysis All reporter assays were performed in triplicate and repeated at least three times. The activity of the mutant at each dose was expressed as a percentage of the maximum WT response, and a four-parameter logistical dose-response curve was fitted using Prism 4 software (GraphPad Software Inc., San Diego, CA). This curve was used to determine the activity of each mutant at the EC50 dose of the wild type (range 15–50 nM), and comparisons to WT activity were made using a one-way ANOVA analysis with the Dunnett’s multiple comparison test.
Western analysis of PROKR2 mutants For expression studies, HEK293 cells were transfected with 100 ng WT or mutant PROKR2 cDNAs as described previously. Thirty six hours after transfection, cells were lysed in Cell Lytic-M buffer (Sigma-Aldrich, St. Louis, MO) and subjected to reduced SDS-PAGE analysis using 10% Tris-HCl Ready Gel (Bio-Rad Laboratories). Resolved proteins were transferred onto polyvinylidene difluoride membrane (Bio-Rad Laboratories, Inc., Hercules, CA) in the presence of 10% methanol. After blocking in Tris-buffered saline supplemented with 5% dry milk and 0.2% Tween 20, blots were probed with anti-V5 antibodies (1:5000 dilution; Invitrogen), and immunoreactivity was visualized using Western Lighting chemiluminescence reagent (PerkinElmer, Boston, MA). To control for equal loading, the blots were then stripped using Restore Western Blot Stripping Buffer (Pierce, Rockford, IL), and reprobed with horseradish peroxidase-conjugated anti-b-actin antibody (1:10,000; Abcamat). Intensity of the immunoreactivity was quantified by densitometry, and the ratio of PROKR2 mutant to β-actin was calculated and compared with wild type. These experiments were performed at least two times.
|
Results |
|---|
|
TopAbstractIntroductionSubjects and MethodsResultsDiscussionReferences |
|---|
PROK2
Of 170 KS and 154 nIHH, we identified five mutations in the PROK2 gene in four KS (2%) and one nIHH (<1%) probands (Tables 1
and 2 and Fig. 1). One mutation was a homozygous deletion [(p.I55fsX1+p.I55fsX1) (c.163delA +c.163delA)] previously reported (21), and the four remaining were heterozygous missense mutations: p.A24P (c.70 G>C) located in the signal peptide; p.C34Y (c.101 G>A); p.I50M (c.150 C>G); and p.R73C (c.217 C>T). The p.R73C mutation has previously been reported in a heterozygous (14) and homozygous state (32). In addition, one heterozygous synonymous change was also identified in a male proband [p.A28A (c.84 C>G)].
|
|
|
No additional mutations were found in KAL1, FGFR1, GPR54, NELF, or GnRHR in probands with PROK2/PROKR2 mutations.
In vitro studies
PROK2 mutants
We examined the signaling properties of four PROK2 mutants (C34Y, I50M, R73C, and I55X) in an aequorin-based luminescence assay to evaluate intracellular calcium mobilization (Fig. 2). The full-length human PROK2 activated PROKR2 at a low concentration (EC50 
50 nM). Mutation C34Y totally abolished the calcium mobilizing activity of PROK2 (>1000-fold reduction at the Ec50 of the wild type). R73C mutant resulted in a 7-fold decreased activity at the EC50 of wild type. The truncated PROK2-27AA (p.I55fsX1) could not activate PROKR2 even at very high concentrations (>200 µM) (21). Of note, the alteration from isoleucine to methionine (I50M) (both hydrophobic amino acids) had a comparable potency as the WT PROK2. The A24P mutant was not assessed in the assay because the mutated residue is found within the signal peptide region.
|
, A and B). Six PROKR2 mutants (Y113H, V115M, R164Q, L173R, W178S, and S188L) showed severely compromised activity in both assays (<40% at EC50 of wid type; P < 0.05). All six mutants demonstrated markedly reduced expression levels (40–70% of wild type; Fig. 3C), suggesting protein instability that may in part explain their poor biological function. In contrast, the R85C mutant within the first intercellular loop was moderately compromised in both assays (56 and 42% of wild type, respectively) but did not reach statistical significance in the transcription assay (P > 0.05 vs. P < 0.01 for the Ca+ assay). The expression of R85C was normal (Fig. 3C). Among the remaining mutants, R248Q located within the last intracellular loop and V331M located within the C-terminal tail had normal transcription activity but decreased activity on calcium mobilization (72 and 48% of wild type, respectively, both <0.05) (Fig. 3, D and E). Finally, the R357W exhibited higher activity compared with the wild type in the transcriptional assay (148% of wild type; P < 0.05; Fig. 3D) and reduced activity in the Ca2+ assay (60% of wild type; P > 0.05), albeit not statistically significant. The expression levels of these three mutants were comparable to the WT PROKR2 (Fig. 3F).
|
Reproductive phenotyping
Four probands with PROK2 mutations, eight of 10 with PROKR2 mutations, and one proband carrying both a PROK2 and PROKR2 mutation, all exhibited absent puberty, and most of them had undetectable serum LH levels (Fig. 4A and Table 2
). However, one proband with absent puberty (no. 11) exhibited a pulsatile pattern of LH and had elevated LH (32 IU/liter) and FSH (27 IU/liter) levels in the setting of hypogonadal T levels (Fig. 4B). This LH secretion pattern is clearly hypergonadotropic but not in the range of males with primary gonadal failure and hypogonadal serum T, suggesting an element of insufficiency of GnRH secretion as well as a primary gonadal resistance, i.e. a dual defect.
|
).
Olfactory phenotyping
Anosmia was documented by history and confirmed by formal smell testing in three of four probands with PROK2 deficiency (nos. 1–3), six of 10 probands with PROKR2 deficiency (nos. 5–10) and in the proband with both a mutation in PROK2 and PROKR2 (no. 15) (Table 1). MRI demonstrated abnormal OB and/or tract in all the KS subjects assessed (nos. 1, 5, 7, 9, 10, and 15). In contrast, a normal sense of smell by history confirmed by quantitative smell testing was documented in patient no. 4 who harbors a PROK2 mutation as well as in four IHH subjects deficient in PROKR2 (nos. 11–14) (Table 1). Two of these subjects (nos. 13 and 14) also had apparently normal olfactory structures by MRI. Thus, mutations in PROK2/PROKR2 underlie both KS and nIHH. No correlations between the olfactory phenotypes and the functionality of the mutants were apparent (Table 2).
Associated phenotypes
Several other nonreproductive phenotypes were noted in this cohort of 15 probands carrying ligand and/or receptor mutations, including epilepsy, hearing loss, synkinesia, fibrous dysplasia, sleep disorder, and other bone phenotypes (Table 1). Renal imaging performed in six probands revealed no anomalies.
Genetics in families with PROK2 and PROKR2 mutations
Figure 5 portrays seven familial cases with PROK2 and PROKR2 mutations. Of interest, pedigree no. 3 portrays a KS proband (case no. 3), his affected KS brother, and their asymptomatic mother, all carrying an heterozygous PROK2 mutation (p.C34Y). Pedigree no. 12 demonstrates a father with delayed puberty and an apparently asymptomatic mother who passed the PROKR2 mutation S188L on to her son (case no. 12). Pedigree no. 13 portrays a proband with nIHH harboring the PROKR2 mutation R248Q (case no. 13), which he inherited from his apparently asymptomatic father. Pedigree no. 10 demonstrates a KS proband carrying the PROKR2 mutation V331M (case no. 10) and several asymptomatic carries within the siblings (incomplete penetrance). These DNA changes in PROK2 and PROKR2 were observed in patients with GnRH deficiency and were not seen in controls, nor were they reported in the growing normative data of the database of single-nucleotide polymorphisms. The S188L mutant was clearly loss of function, whereas R248Q and V331M mutants exhibited only mild decreased calcium influx. Given the previous report of multiple gene defects synergizing to cause human GnRH deficiency (10, 14), it is likely that other as-yet-to-be-described gene defects exist in these three pedigrees.
|
|
Discussion |
|---|
|
TopAbstractIntroductionSubjects and MethodsResultsDiscussionReferences |
|---|
2% for both). These data expand the phenotypical spectrum of PROK2 and PROKR2 mutations in the human, and indicate that this system plays a role in GnRH neuron development beyond OB morphogenesis. Functional studies of mutant PROK2 demonstrate that C34Y, I55fsX, and R73C exhibit decreased intracellular calcium mobilization. The C34Y and R73C mutations alter the constitution of the conserved cysteines in the PROK2 (33) and could result in misfolding of the peptide and loss of function. The I55fsX may result in a 27AA truncated protein with no activity (21). Alternatively, this premature stop codon may result in mRNA decay and no resulting protein (34). In contrast, the mutant I50M had a similar potency as WT PROK2 for intracellular calcium mobilization, presumably because this mutation does not alter the hydrophobic property of the amino acid at this site. Nevertheless, I50M mutant may cause defects in other aspects of the PROK2 signaling pathways.
Most receptor mutants exhibit decreased expression, reduced ability to activate MAPK pathways, and reduced Ca2+ influx. Of interest, V331M, R248Q, and R357W mutants compromised Ca2+ influx despite maintaining normal or high activity in the MAPK transcription assay, suggesting that not all PROKR2 mutants activate downstream signaling pathways in the same way (Fig. 3B).
All KS probands with PROK2 or PROKR2 deficiency presented with a severe phenotype, including anosmia, absent puberty, undetectable LH levels, and a high frequency of cryptorchidism (40%), the latter indicating GnRH deficiency beginning in utero. These phenotypes are reminiscent of Prok2 and Prokr2 deficient mice, which exhibit OB dysgenesis and hypogonadotropism with immature testis and absent/severely reduced numbers of hypothalamic GnRH neurons (21, 22, 23). Studies of Prok2 deficient mice revealed GnRH neurons arrested between the two dysgenic OBs, a finding consistent with a migratory defect (21). Because PROKR2 and GnRH did not colocalize (21), decreased PROK2 signaling appears to impair GnRH neuron migration indirectly, likely through OB dysgenesis and/or impaired olfactory axon migration.
Here, we also demonstrate that PROK2 and PROKR2 deficiencies cause not only KS but also nIHH. In contrast to the KS probands, two of five nIHH probands exhibited partial spontaneous puberty evidenced by testicular growth (no. 13) and breast development (no. 14). Interestingly, the IHH male with partial puberty underwent spontaneous reversal of his GnRH deficiency later in life after androgen treatment. This patient with a PROKR2 mutation adds to the recent series of IHH reversal (3) and suggests that gene-environment interactions may modify a phenotype later in life. Consistently, the two corresponding mutant receptors (R248Q and R85C) displayed a mild loss of function. These human studies suggest an additional role for PROK2 signaling in GnRH neuron development/function beyond OB development. Of note, PROK2 has been a crucial "second messenger" output protein from the suprachiasmatic nucleus to various peripheral systems such as the locomotor, thermogenesis, etc. (35). Thus, it is possible that the PROK2 system contributes to the pathogenesis of nIHH in other ways such as altering GnRH pacemaking.
Our clinical investigations also suggest a role for the PROK2 system in gonadal development and function. Indeed, subject no. 11 failed to go through puberty yet exhibited a clear hypergonadotropic baseline LH secretory pattern (in the presence of hypogonadal serum T). However, these elevated gonadotropin levels are lower than expected, given the castrate T levels (T <60 ng/dl), indicating a dual hypothalamic and gonadal defect. Interestingly, both PROK2 and PROKR2 are expressed in the developing and adult testis (Genomics Institute of the Novartis Research Foundation SymAtlas; San Diego CA). The impaired GnRH secretion in this patient, albeit incomplete, is also consistent with his father’s history of delayed puberty.
Beyond their reproductive and variable olfactory phenotypes, IHH patients with deficiencies in PROK2/PROKR2 also exhibit hearing loss, synkinesia, and epilepsy with variable frequency suggesting additional developmental roles of the PROK2/PROKR2 system. Synkinesia has been reported in subjects carrying KAL1 or FGFR1 mutations (no. 1499 in Ref. 4). Generalized epilepsy in patients with PROK2/PROKR2 mutations is notable in light of decreased epileptic threshold in Prok2 –/– mice (Q.-Y.Z., unpublished data). Finally, the patient harboring both the heterozygous PROK2 and PROKR2 mutations has a history of sleep disorder, a phenotype that has been previously described in a KS patient with a heterozygous PROK2 mutation (14). Given the report of circadian anomalies in mice deficient in Prok2 (20), further studies are needed to elucidate a potential defect in the circadian rhythm in subjects harboring these mutations.
Severe GnRH deficiency in both IHH probands with heterozygous and homozygous PROK2 mutations is unusual because homozygous mutations would be expected to result in a more severe phenotype. In addition, several asymptomatic carriers and/or milder phenotypes in probands’ family members with PROK2/PROKR2 mutations were identified. Furthermore, one KS subject harbored a mutation in both PROK2 and PROKR2. These data are consistent with previous findings of an oligogenic model for IHH (10, 14). Because only approximately 30% of IHH cases have a known genetic defect, we expect to document more cases of oligogenicity in IHH as novel loci are identified.
This report confirms the role of the PROK2 system in the pathogenesis of human GnRH deficiency with a wide range of both reproductive and nonreproductive phenotypes. We report mutations in both nIHH and KS indicating that the role of the prokineticin system must go well beyond that of the developing OB. Therefore, mutations in PROK2 and PROKR2 should be considered in all GnRH deficient subjects with or without anosmia. Elucidating the pathways involved in PROK2 signaling in GnRH deficient subjects will allow us to understand better its role in human reproduction.
|
Footnotes |
|---|
Disclosure Statement: The authors have nothing to declare.
First Published Online June 17, 2008
Abbreviations: CHO, Chinese hamster ovary; Egr, early growth response; E2, estradiol; FGFR1, Fibroblast Growth Factor Receptor 1; GNRHR, Gonadotropin Releasing Hormone Receptor; GPR54, G Protein Couple Receptor 54; IHH, idiopathic hypogonadotropic hypogonadism; KS, Kallmann syndrome; MGH, Massachusetts General Hospital; MRI, magnetic resonance imaging; NELF, Nasal Embryonic LHRH Factor; nIHH, normosmic idiopathic hypogonadotropic hypogonadism; OB, olfactory bulb; PROK2, prokineticin 2; PROKR2, prokineticin receptor 2; T, testosterone; WT, wild-type.
Received December 3, 2007.
Accepted June 6, 2008.
|
References |
|---|
|
TopAbstractIntroductionSubjects and MethodsResultsDiscussionReferences |
|---|
This article has been cited by other articles:
 |
|
 |
|
  T. Raivio, Y. Sidis, L. Plummer, H. Chen, J. Ma, A. Mukherjee, E. Jacobson-Dickman, R. Quinton, G. Van Vliet, H. Lavoie, et al. Impaired Fibroblast Growth Factor Receptor 1 Signaling as a Cause of Normosmic Idiopathic Hypogonadotropic Hypogonadism J. Clin. Endocrinol. Metab., November 1, 2009; 94(11): 4380 - 4390. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-M. Chan, A. de Guillebon, M. Lang-Muritano, L. Plummer, F. Cerrato, S. Tsiaras, A. Gaspert, H. B. Lavoie, C.-H. Wu, W. F. Crowley Jr., et al. GNRH1 mutations in patients with idiopathic hypogonadotropic hypogonadism PNAS, July 14, 2009; 106(28): 11703 - 11708. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Monnier, C. Dode, L. Fabre, L. Teixeira, G. Labesse, J.-P. Pin, J.-P. Hardelin, and P. Rondard PROKR2 missense mutations associated with Kallmann syndrome impair receptor signalling activity Hum. Mol. Genet., January 1, 2009; 18(1): 75 - 81. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
